Skip to content


Calliditas leverages considerable experience in drug development and proprietary formulation expertise to selectively explore treatments for orphan diseases in which there is strong rationale and high unmet need. To that end, we seek to maximize the potential of our products by commercializing on a standalone basis in the United States market and through strategic partnerships in other regions. Additionally, we are interested in enhancing our product portfolio by identifying and in-licensing additional, late-stage product candidates that are a strong strategic and commercial fit.

Interim Report Q1 2024

The interim report for the first quarter, January – March 2024 was published 23 May 2024 at 07.00 a.m. CEST.

Webcast: at 14:30 p.m. CEST the same day

IR Contact

Åsa web photo (1)

Åsa Hillsten

Head of IR and Sustainability